Pfizer Inc (PFE-N) Stock Predictions - Stockchase
WATCH LIST
634
Pfizer Inc (PFE-N)

ON STOCKCHASE SINCE Oct 2000

biotechnology/pharmaceutical

Pfizer Inc Pfizer Inc
PFE-N

61 634
biotechnology/pharmaceutical

Pfizer Inc (PFE-N) SAVE

44.06

0.31 (0.71%)

Sep, 22, 2018, 12:00 am

OPINIONS

About Pfizer Inc (PFE-N)

Pfizer Inc. is an American pharmaceutical corporation headquartered in New York City, with its research headquarters in Groton, Connecticut. Pfizer is considered one of the world's largest pharmaceutical companies. More at Wikipedia

What the experts are saying about PFE-N



  • All
  • Filtered
Signal Opinion Expert
HOLD
Pfizer Inc(PFE-N) 

August 23, 2018

Very much a value stock. Not a lot of growth. You can’t too far wrong at these levels. He likes a little more growth.  

biotechnology/pharmaceutical

Very much a value stock. Not a lot of growth. You can’t too far wrong at these levels. He likes a little more growth.  

biotechnology/pharmaceutical
Don Lato

President, Padlock Investment M...

Price Price
$42.200
Owned Owned
No

DON'T BUY
Pfizer Inc(PFE-N) 

August 7, 2018

Not a big owner of pharmaceuticals, because they’re under pricing pressure. Pfizer’s thinking of selling off consumer division. It’s OK, but the medical device sector’s doing better than pharma. Whole sector’s not performing well. Only pharma he owns is Novo Nordisk.

biotechnology/pharmaceutical

Not a big owner of pharmaceuticals, because they’re under pricing pressure. Pfizer’s thinking of selling off consumer division. It’s OK, but the medical device sector’s doing better than pharma. Whole sector’s not performing well. Only pharma he owns is Novo Nordisk.

biotechnology/pharmaceutical
David Driscoll

President , Liberty Internationa...

Price Price
$40.840
Owned Owned
No

PAST TOP PICK
Pfizer Inc(PFE-N) 

July 25, 2018

(A Top Pick May 31/17 Up 20%)  A stable, old-school pharma company.  They can still spin out some businesses and they have a lot good projects in the pipeline.  

biotechnology/pharmaceutical

(A Top Pick May 31/17 Up 20%)  A stable, old-school pharma company.  They can still spin out some businesses and they have a lot good projects in the pipeline.  

biotechnology/pharmaceutical
Michael Simpson

Senior Vic, Sentry Investments...

Price Price
$37.990
Owned Owned
Yes

BUY
Pfizer Inc(PFE-N) 

July 5, 2018

140 drugs that generate over $100 million in revenues. They have a good pipeline. Some interesting data on pain medication. Consistent revenue. Great valuation. There is no reason why this company shouldn’t be trading at 14 times earnings and it is trading at 11.5x. he expects a multiple expansion.

biotechnology/pharmaceutical

140 drugs that generate over $100 million in revenues. They have a good pipeline. Some interesting data on pain medication. Consistent revenue. Great valuation. There is no reason why this company shouldn’t be trading at 14 times earnings and it is trading at 11.5x. he expects a multiple expansion.

biotechnology/pharmaceutical
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$36.870
Owned Owned
Yes

PAST TOP PICK
Pfizer Inc(PFE-N) 

May 29, 2018

(A Top Pick June 16/17, Up 12% ) Likes pharma and owns a couple of them. The time to buy is when they are facing a patent clift, and their biggest drugs are coming off-patents and the company has to find new drugs or buy other promising companies. Pfizer was one of those when they bought Wyeth. They have a big consumer products division, which provides lots of cash flow, good earnings but not huge growth, which they put up for sell recently but couldn’t really find a buyer. Still likes it longer term.

biotechnology/pharmaceutical

(A Top Pick June 16/17, Up 12% ) Likes pharma and owns a couple of them. The time to buy is when they are facing a patent clift, and their biggest drugs are coming off-patents and the company has to find new drugs or buy other promising companies. Pfizer was one of those when they bought Wyeth. They have a big consumer products division, which provides lots of cash flow, good earnings but not huge growth, which they put up for sell recently but couldn’t really find a buyer. Still likes it longer term.

biotechnology/pharmaceutical
Norman Levine

Managing D, Portfolio Management...

Price Price
$35.700
Owned Owned
Unknown

PAST TOP PICK
Pfizer Inc(PFE-N) 

April 27, 2018

(A Top Pick September 5/17 Up 12%)   He still likes this, including the close to 4% yield.  It is probably the “bluest” blue chip out there in the health sector. 

biotechnology/pharmaceutical

(A Top Pick September 5/17 Up 12%)   He still likes this, including the close to 4% yield.  It is probably the “bluest” blue chip out there in the health sector. 

biotechnology/pharmaceutical
David Dietze

Founder, P, Point View Wealth Ma...

Price Price
$37.000
Owned Owned
Yes

DON'T BUY
Pfizer Inc(PFE-N) 

April 25, 2018

He's gone the biotech route in the drug sector. Over the years, he has owned the big pharmas, but their growth has stagnated with growth in earnings done through cost containment--and you can't cut forever. Topline growth is better which is where he looks first in a stock. Pfizer hasn't had this.

biotechnology/pharmaceutical

He's gone the biotech route in the drug sector. Over the years, he has owned the big pharmas, but their growth has stagnated with growth in earnings done through cost containment--and you can't cut forever. Topline growth is better which is where he looks first in a stock. Pfizer hasn't had this.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment ...

Price Price
$36.680
Owned Owned
No

DON'T BUY
Pfizer Inc(PFE-N) 

April 9, 2018

It's trading where it was 20 years ago, as with many large US drug stocks, due to tough FDA approval. He's very cautious in this sector. All countries are struggling with rising health costs.

biotechnology/pharmaceutical

It's trading where it was 20 years ago, as with many large US drug stocks, due to tough FDA approval. He's very cautious in this sector. All countries are struggling with rising health costs.

biotechnology/pharmaceutical
Lorne Steinberg

President , Lorne Steinberg Weal...

Price Price
$35.460
Owned Owned
Unknown

BUY
Pfizer Inc(PFE-N) 

March 21, 2018

Teva or Pfizer?  He sold Teva 18 months ago. Generic drug prices are under pressure though have levelled off. Their migraine drug has struggled. Instead, he prefers Pfizer with 140 drugs generating $100 million in revenues. They make good acquisitions and are enjoying great progress in oncology. They're also repatriating $24.5 billion with $5 million going to buybacks. Just announced they want to sell their consumer products division, so the impact of this is unknown. 12x forward earnings. Fabulously run company. Talk of major acquisitions. Happy to hold this.

biotechnology/pharmaceutical

Teva or Pfizer?  He sold Teva 18 months ago. Generic drug prices are under pressure though have levelled off. Their migraine drug has struggled. Instead, he prefers Pfizer with 140 drugs generating $100 million in revenues. They make good acquisitions and are enjoying great progress in oncology. They're also repatriating $24.5 billion with $5 million going to buybacks. Just announced they want to sell their consumer products division, so the impact of this is unknown. 12x forward earnings. Fabulously run company. Talk of major acquisitions. Happy to hold this.

biotechnology/pharmaceutical
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$36.270
Owned Owned
Unknown

BUY
Pfizer Inc(PFE-N) 

March 13, 2018

Likes healthcare. Boasts a 3.7% yield that'll likely increase, decent cash flow and growth. Company could spin-off.

biotechnology/pharmaceutical

Likes healthcare. Boasts a 3.7% yield that'll likely increase, decent cash flow and growth. Company could spin-off.

biotechnology/pharmaceutical
Stan Wong

Director &, Private Wealth Manag...

Price Price
$36.750
Owned Owned
No

COMMENT
Pfizer Inc(PFE-N) 

March 8, 2018

Like many of the other major pharma companies has gone through their patent cliffs. It is trading at an attractive multiple and has an attractive dividend yield. She prefers Johnson & Johnson (JNJ-O).

biotechnology/pharmaceutical

Like many of the other major pharma companies has gone through their patent cliffs. It is trading at an attractive multiple and has an attractive dividend yield. She prefers Johnson & Johnson (JNJ-O).

biotechnology/pharmaceutical
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$36.770
Owned Owned
No

COMMENT
Pfizer Inc(PFE-N) 

February 14, 2018

Likes healthcare, but he has a tough time with drug companies. It takes a long time to get a patent with lots of research. Pfzier, though, has legacy, long-term drugs to draw on. This is an income vehicle. Doesn't expect new products right now. An income, not a growth play.

biotechnology/pharmaceutical

Likes healthcare, but he has a tough time with drug companies. It takes a long time to get a patent with lots of research. Pfzier, though, has legacy, long-term drugs to draw on. This is an income vehicle. Doesn't expect new products right now. An income, not a growth play.

biotechnology/pharmaceutical
Zachary Curry

Chief Oper, Davis-Rea Ltd....

Price Price
$35.190
Owned Owned
Unknown

DON'T BUY
Pfizer Inc(PFE-N) 

January 29, 2018

You could ask if there is a better way to hold it so that you get a currency hedge.  ZUH-T does this to give you healthcare sector exposure.  He would wait until the dollar moves back to 77 cents.  If the Canadian dollar was higher than 80 cents you would not want hedged exposure.

biotechnology/pharmaceutical

You could ask if there is a better way to hold it so that you get a currency hedge.  ZUH-T does this to give you healthcare sector exposure.  He would wait until the dollar moves back to 77 cents.  If the Canadian dollar was higher than 80 cents you would not want hedged exposure.

biotechnology/pharmaceutical
Larry Berman CF

Chief Inve, ETF Capital Manageme...

Price Price
$39.020
Owned Owned
Unknown

HOLD
Pfizer Inc(PFE-N) 

January 29, 2018

If you exclude the impact of the Hosperian Fusion System divestiture, revenues for the quarter increased 4%. They've done OK, but thank God for tax cuts, because on a dividend standard, they've had 9% five-year growth, but the average for 10 years has been 1%.

biotechnology/pharmaceutical

If you exclude the impact of the Hosperian Fusion System divestiture, revenues for the quarter increased 4%. They've done OK, but thank God for tax cuts, because on a dividend standard, they've had 9% five-year growth, but the average for 10 years has been 1%.

biotechnology/pharmaceutical
David Driscoll

President , Liberty Internationa...

Price Price
$39.020
Owned Owned
Unknown

DON'T BUY
Pfizer Inc(PFE-N) 

January 19, 2018

He would not be a buyer. The company has a fairly well-defined top, about $2 higher than what it is right now. Also doesn't have a lot of FMV potential. The stock has been struggling to get higher and it hasn't been dynamic. Thinks that when it hits technical resistance and FMV resistance at the same time, it's toast. If you own, you could hold it for another $1, but that would be it.

biotechnology/pharmaceutical

He would not be a buyer. The company has a fairly well-defined top, about $2 higher than what it is right now. Also doesn't have a lot of FMV potential. The stock has been struggling to get higher and it hasn't been dynamic. Thinks that when it hits technical resistance and FMV resistance at the same time, it's toast. If you own, you could hold it for another $1, but that would be it.

biotechnology/pharmaceutical
Ross Healy

Chairman, Strategic Analysis C...

Price Price
$36.940
Owned Owned
No

Showing 1 to 15 of 634 entries

No Comments.


You must be logged in to comment.

Successfully Saved Company
Successfully Saved Company